Skip to main content
SpringerLink
Log in

Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Certain commonly taken pharmaceutical preparations induce increased levels of plasma prolactin. The effects of these drugs on (a) tumor steroid receptors and metabolism, and (b) plasma hormones and hormone binding proteins have been studied in postmenopausal women with breast cancer. Two groups have been compared, 18 patients on drug treatment for at least 2 months and 15 subjects with no history of drug ingestion. Patients taking medication had significantly higher levels of plasma prolactin compared with control women. No significant difference was observed between the groups with regard to the plasma concentrations of dehydroepiandrosterone (DHA) and its sulphate (DHS), testosterone, estrone, estradiol-17β, sex hormone binding globulin (SHBG), and albumin. Similarly, no difference was observed between these two groups with regard to estrogen receptor (ER), progestogen receptor (PR), or androgen receptor (AR) levels in the tumors nor their ability to metabolize (7−3H) testosterone. It is considered that the ingestion of these drugs does not affect tumor mechanisms involving steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Department of Health and Social Security, Personal communication, 1981

  2. Stoll BA:In BA Stoll (ed). Risk Factors in Breast Cancer. Heinemann Medical Books, London, 1976, p 193

    Google Scholar 

  3. Turkington RW: Prolactin secretion in patients treated with various drugs. Arch Intern Med 130:349, 1972

    Article  PubMed  CAS  Google Scholar 

  4. Kleinberg DL, Noel LE, Frantz AE: Chlorpromazine stimulation and L-Dopa suppression of plasma prolactin in man. J Clin Endocrinol Metab 33:873, 1971

    CAS  Google Scholar 

  5. Langer E, Ferin M, Soeher EJ: Effect of haloperidol and L-Dopa on plasma prolactin in stalk sectioned and intact monkeys. Endocrinology 102:367, 1978

    PubMed  CAS  Google Scholar 

  6. Horrobin DF: Prolactin: Physiology and Clinical Significance. Medical and Technical Publishing Co Ltd, 1973, p 105

  7. Meyles L (ed): Side Effects of Drugs. Excerpta Medica Foundations, 1963, p 32

  8. Judd SJ, Lazarus L, Smythe G: Prolactin secretion by metoclopramide in man. J Clin Endocrinol Metab 43:313, 1976

    PubMed  CAS  Google Scholar 

  9. Burland WL, Gleadle RI, Lee RM, Rowley-Jones D, Groom GU: Prolactin response to cimetidine. Br J Clin Pharmacol 7:19, 1979

    PubMed  CAS  Google Scholar 

  10. Wilson RG, Buchan R, Roberts MM, Forest APM, Boyns AR, Cole EN, Griffiths K: Prolactin and breast cancer. Proceedings of the Royal Society of Medicine 66:865, 1973

    PubMed  CAS  Google Scholar 

  11. Robyn C, Delvoye P, Nokin J, Vekemans M, Badawi M, Perez Lopez FR, L'Hermite M.In JL Pasteels and C Robyn (ed). Human Prolactin. Excerpta Medica, 1972, p 167

  12. Welsch CW, Nagasawa H: Prolactin and murine mammary tumorigenesis. Cancer Res 37:951, 1977

    PubMed  CAS  Google Scholar 

  13. Buchan P, Fraser AT, Miller WR: The effect of perphenazine treatment on testosterone metabolism by established rat mammary carcinomas. Biochem Soc Trans 4:1100, 1976

    PubMed  CAS  Google Scholar 

  14. Shafie S, Brooks SC: The effect of prolactin on growth and estrogen receptor level of human breast cancer. Cancer Res 37:792, 1977

    PubMed  CAS  Google Scholar 

  15. Vermeulen A, Ando S: Prolactin and adrenal androgen secretion. Clin Endocrinol 8:295, 1978

    CAS  Google Scholar 

  16. Wang DY, Moore JW, Thomas BS, Bulbrook RD, Hoare SA, Tong D, Hayward JL: Plasma and urinary androgens in women with varying degrees of risk of breast cancer. Eur J Cancer 15:1269, 1979

    PubMed  CAS  Google Scholar 

  17. Hwang P, Robertson M, Guyda H, Friesen H: The purification of human prolactin from frozen pituitary glands. J Clin Endocrinol Metab 36:1110, 1973

    Article  PubMed  CAS  Google Scholar 

  18. Bagshaw KD: Computer controlled automated radioimmunoassay. Laboratory Practice 24:573, 1975

    Google Scholar 

  19. Buster JE, Abraham GE: Radioimmunoassay of plasma dehydroepiandrosterone sulphate. Anal Lett 5:543, 1973

    Google Scholar 

  20. Hillier SG, Brownsey BG, Cameron EHD: Some observations on the determination of testosterone in human plasma by radioimmunoassay using antisera raised against testosterone-3-BSA and testosterone-11-BSA. Steroids 21:735, 1975

    Article  Google Scholar 

  21. Rosner W: A simplified method for the quantitative determination of testosterone oestradiol binding globulin activity in human plasma. J Clin Endocrinol Metab 34:983, 1972

    PubMed  CAS  Google Scholar 

  22. Hawkins RA, Hill A, Freedman B: A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta 64:203, 1975

    Article  PubMed  CAS  Google Scholar 

  23. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660, 1949

    Article  CAS  Google Scholar 

  24. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248, 1976

    Article  PubMed  CAS  Google Scholar 

  25. Miller WR, Forrest APM: Oestradiol synthesis by a human breast carcinoma. Lancet 2:866, 1974

    Article  PubMed  CAS  Google Scholar 

  26. Miller WR, Forrest APM, Hamilton T: Steroid metabolism by human breast and rat mammary carcinoma. Steroids 23:379, 1974

    Article  PubMed  CAS  Google Scholar 

  27. Wilson RG: MD Thesis, University of Nottingham, 1976.

  28. De Waard F, Kwa HG, Poortman J: Plasma prolactin levels in women at postmenopausal age with a family history of breast cancer or a prescription for antihypertensive rauwolfia treatment. Oncology 37:33, 1980

    Article  PubMed  Google Scholar 

  29. Metcalf ME, Espiner EA, Donald RA: Lack of effect of prolactin suppression on plasma dehydroepiandrosterone sulphate. Endocrinology 10:539, 1979

    CAS  Google Scholar 

  30. Parker L, Perrigo V, Skowsky R: Lack of adrenal androgen stimulation by ACTH in extreme hyperprolactinaemia. Arch Androl 3:259, 1979

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Clinical Surgery, Royal Infirmary, EH3 9YW, Edinburgh, UK

    R. C. Mason, W. R. Miller, R. A. Hawkins & A. P. M. Forrest

  2. Immunoassay Section, Department of Clinical Chemistry, Royal Infirmary, EH3 9YW, Edinburgh, UK

    M. S. Brown

Authors
  1. R. C. Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. R. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. A. Hawkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. S. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. P. M. Forrest
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mason, R.C., Miller, W.R., Hawkins, R.A. et al. Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer. Breast Cancer Res Tr 3, 331–338 (1983). https://doi.org/10.1007/BF01807585

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807585

Keywords

Search

Navigation